View Future GrowthUbionLtd 過去の業績過去 基準チェック /06UbionLtdの収益は年間平均-15.5%の割合で減少していますが、 Consumer Services業界の収益は年間 増加しています。収益は年間4.2% 15.2%割合で 減少しています。主要情報-15.48%収益成長率-20.51%EPS成長率Consumer Services 業界の成長13.57%収益成長率-15.18%株主資本利益率-0.50%ネット・マージン-0.043%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Feb 24First quarter 2026 earnings released: EPS: ₩2.00 (vs ₩70.00 in 1Q 2025)First quarter 2026 results: EPS: ₩2.00 (down from ₩70.00 in 1Q 2025). Revenue: ₩8.14b (down 27% from 1Q 2025). Net income: ₩32.8m (down 98% from 1Q 2025). Profit margin: 0.4% (down from 13% in 1Q 2025). The decrease in margin was driven by lower revenue.Reported Earnings • Dec 17Full year 2025 earnings released: EPS: ₩68.00 (vs ₩142 loss in FY 2024)Full year 2025 results: EPS: ₩68.00 (up from ₩142 loss in FY 2024). Revenue: ₩33.7b (up 1.2% from FY 2024). Net income: ₩1.34b (up ₩4.14b from FY 2024). Profit margin: 4.0% (up from net loss in FY 2024). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.Reported Earnings • Feb 20First quarter 2025 earnings released: EPS: ₩70.00 (vs ₩11.00 loss in 1Q 2024)First quarter 2025 results: EPS: ₩70.00 (up from ₩11.00 loss in 1Q 2024). Revenue: ₩11.1b (up 36% from 1Q 2024). Net income: ₩1.39b (up ₩1.61b from 1Q 2024). Profit margin: 13% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue.Reported Earnings • Dec 17Full year 2024 earnings released: ₩142 loss per share (vs ₩28.00 loss in FY 2023)Full year 2024 results: ₩142 loss per share (further deteriorated from ₩28.00 loss in FY 2023). Revenue: ₩33.3b (up 4.6% from FY 2023). Net loss: ₩2.80b (loss widened 414% from FY 2023).Reported Earnings • Sep 02Third quarter 2024 earnings released: ₩23.00 loss per share (vs ₩17.00 loss in 3Q 2023)Third quarter 2024 results: ₩23.00 loss per share (further deteriorated from ₩17.00 loss in 3Q 2023). Revenue: ₩9.22b (up 17% from 3Q 2023). Net loss: ₩468.8m (loss widened ₩420.4m from 3Q 2023).Reported Earnings • Mar 06First quarter 2024 earnings released: ₩11.00 loss per share (vs ₩11.09 profit in 1Q 2023)First quarter 2024 results: ₩11.00 loss per share (down from ₩11.09 profit in 1Q 2023). Revenue: ₩8.17b (up 17% from 1Q 2023). Net loss: ₩225.7m (down 221% from profit in 1Q 2023).すべての更新を表示Recent updatesお知らせ • Apr 14Ubion Co.Ltd. (KOSDAQ:A084440) announces an Equity Buyback for KRW 600 million worth of its shares.Ubion Co.Ltd. (KOSDAQ:A084440) announces a share repurchase program. Under the program, the company will repurchase up to KRW 600 million worth of it's shares. The purpose of the program is to enhance shareholder value and provide performance-based compensation for employees and executives. The program will expire on October 14, 2026. As of April 12, 2026, the company had 580,379 shares in treasury within scope available for dividend and had 0 shares under other acquisitions.Reported Earnings • Feb 24First quarter 2026 earnings released: EPS: ₩2.00 (vs ₩70.00 in 1Q 2025)First quarter 2026 results: EPS: ₩2.00 (down from ₩70.00 in 1Q 2025). Revenue: ₩8.14b (down 27% from 1Q 2025). Net income: ₩32.8m (down 98% from 1Q 2025). Profit margin: 0.4% (down from 13% in 1Q 2025). The decrease in margin was driven by lower revenue.New Risk • Feb 24New major risk - Revenue and earnings growthEarnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩20.6b market cap, or US$14.3m).お知らせ • Jan 21Ubion Co.Ltd. (KOSDAQ:A084440) announces an Equity Buyback for KRW 600 million worth of its shares.Ubion Co.Ltd. (KOSDAQ:A084440) announces a share repurchase program. Under the program, the company will repurchase up to KRW 600 million worth of it's shares. The purpose of the program is to enhance shareholder value and provide performance-based compensation for employees and executives. The program will expire on July 22, 2026. As of January 20, 2026, the company had 0 shares in treasury within scope available for dividend and had 0 shares under other acquisitions.Reported Earnings • Dec 17Full year 2025 earnings released: EPS: ₩68.00 (vs ₩142 loss in FY 2024)Full year 2025 results: EPS: ₩68.00 (up from ₩142 loss in FY 2024). Revenue: ₩33.7b (up 1.2% from FY 2024). Net income: ₩1.34b (up ₩4.14b from FY 2024). Profit margin: 4.0% (up from net loss in FY 2024). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.分析記事 • Aug 22These 4 Measures Indicate That UbionLtd (KOSDAQ:084440) Is Using Debt ExtensivelyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Feb 20First quarter 2025 earnings released: EPS: ₩70.00 (vs ₩11.00 loss in 1Q 2024)First quarter 2025 results: EPS: ₩70.00 (up from ₩11.00 loss in 1Q 2024). Revenue: ₩11.1b (up 36% from 1Q 2024). Net income: ₩1.39b (up ₩1.61b from 1Q 2024). Profit margin: 13% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue.分析記事 • Dec 18UbionLtd (KOSDAQ:084440) Is Making Moderate Use Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Dec 17Full year 2024 earnings released: ₩142 loss per share (vs ₩28.00 loss in FY 2023)Full year 2024 results: ₩142 loss per share (further deteriorated from ₩28.00 loss in FY 2023). Revenue: ₩33.3b (up 4.6% from FY 2023). Net loss: ₩2.80b (loss widened 414% from FY 2023).お知らせ • Dec 13Ubion Co.Ltd., Annual General Meeting, Dec 27, 2024Ubion Co.Ltd., Annual General Meeting, Dec 27, 2024, at 11:00 Tokyo Standard Time. Location: seminar room, guro-gu, seoul South KoreaNew Risk • Nov 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue has declined by 4.5% over the past year. Minor Risk Market cap is less than US$100m (₩15.1b market cap, or US$10.7m).Reported Earnings • Sep 02Third quarter 2024 earnings released: ₩23.00 loss per share (vs ₩17.00 loss in 3Q 2023)Third quarter 2024 results: ₩23.00 loss per share (further deteriorated from ₩17.00 loss in 3Q 2023). Revenue: ₩9.22b (up 17% from 3Q 2023). Net loss: ₩468.8m (loss widened ₩420.4m from 3Q 2023).Reported Earnings • Mar 06First quarter 2024 earnings released: ₩11.00 loss per share (vs ₩11.09 profit in 1Q 2023)First quarter 2024 results: ₩11.00 loss per share (down from ₩11.09 profit in 1Q 2023). Revenue: ₩8.17b (up 17% from 1Q 2023). Net loss: ₩225.7m (down 221% from profit in 1Q 2023).New Risk • Jun 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Shareholders have been diluted in the past year (32% increase in shares outstanding). Market cap is less than US$100m (₩38.3b market cap, or US$29.6m).Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Is New 90 Day High Low • Feb 24New 90-day high: ₩5,050The company is up 32% from its price of ₩3,825 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Services industry, which is up 4.0% over the same period.Is New 90 Day High Low • Dec 14New 90-day low: ₩3,150The company is down 6.0% from its price of ₩3,350 on 15 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Services industry, which is up 6.0% over the same period.Is New 90 Day High Low • Oct 28New 90-day high: ₩3,700The company is up 24% from its price of ₩2,990 on 30 July 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Services industry, which is up 3.0% over the same period.Is New 90 Day High Low • Sep 25New 90-day high: ₩3,600The company is up 21% from its price of ₩2,980 on 26 June 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Services industry, which is down 3.0% over the same period.収支内訳UbionLtd の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSDAQ:A084440 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Dec 2530,716-1312,4141,99330 Sep 2533,6841,34012,4442,04130 Jun 2537,36728014,0221,31231 Mar 2537,31318213,1981,31231 Dec 2436,212-1,18813,0391,43830 Sep 2433,282-2,80010,9972,13530 Jun 2431,251-2,4839,8302,44731 Mar 2429,884-2,0639,1872,44731 Dec 2331,728-2927,9033,17130 Sep 2331,832-5449,1622,47930 Jun 2332,7243649,1642,29030 Sep 2231,4612,1519,3951,690質の高い収益: A084440は現在利益が出ていません。利益率の向上: A084440は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A084440は利益が出ておらず、過去 5 年間で損失は年間15.5%の割合で増加しています。成長の加速: A084440の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: A084440は利益が出ていないため、過去 1 年間の収益成長をConsumer Services業界 ( 37.9% ) と比較することは困難です。株主資本利益率高いROE: A084440は現在利益が出ていないため、自己資本利益率 ( -0.5% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YConsumer-services 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 12:41終値2026/05/22 00:00収益2025/12/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ubion Co.Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Feb 24First quarter 2026 earnings released: EPS: ₩2.00 (vs ₩70.00 in 1Q 2025)First quarter 2026 results: EPS: ₩2.00 (down from ₩70.00 in 1Q 2025). Revenue: ₩8.14b (down 27% from 1Q 2025). Net income: ₩32.8m (down 98% from 1Q 2025). Profit margin: 0.4% (down from 13% in 1Q 2025). The decrease in margin was driven by lower revenue.
Reported Earnings • Dec 17Full year 2025 earnings released: EPS: ₩68.00 (vs ₩142 loss in FY 2024)Full year 2025 results: EPS: ₩68.00 (up from ₩142 loss in FY 2024). Revenue: ₩33.7b (up 1.2% from FY 2024). Net income: ₩1.34b (up ₩4.14b from FY 2024). Profit margin: 4.0% (up from net loss in FY 2024). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
Reported Earnings • Feb 20First quarter 2025 earnings released: EPS: ₩70.00 (vs ₩11.00 loss in 1Q 2024)First quarter 2025 results: EPS: ₩70.00 (up from ₩11.00 loss in 1Q 2024). Revenue: ₩11.1b (up 36% from 1Q 2024). Net income: ₩1.39b (up ₩1.61b from 1Q 2024). Profit margin: 13% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue.
Reported Earnings • Dec 17Full year 2024 earnings released: ₩142 loss per share (vs ₩28.00 loss in FY 2023)Full year 2024 results: ₩142 loss per share (further deteriorated from ₩28.00 loss in FY 2023). Revenue: ₩33.3b (up 4.6% from FY 2023). Net loss: ₩2.80b (loss widened 414% from FY 2023).
Reported Earnings • Sep 02Third quarter 2024 earnings released: ₩23.00 loss per share (vs ₩17.00 loss in 3Q 2023)Third quarter 2024 results: ₩23.00 loss per share (further deteriorated from ₩17.00 loss in 3Q 2023). Revenue: ₩9.22b (up 17% from 3Q 2023). Net loss: ₩468.8m (loss widened ₩420.4m from 3Q 2023).
Reported Earnings • Mar 06First quarter 2024 earnings released: ₩11.00 loss per share (vs ₩11.09 profit in 1Q 2023)First quarter 2024 results: ₩11.00 loss per share (down from ₩11.09 profit in 1Q 2023). Revenue: ₩8.17b (up 17% from 1Q 2023). Net loss: ₩225.7m (down 221% from profit in 1Q 2023).
お知らせ • Apr 14Ubion Co.Ltd. (KOSDAQ:A084440) announces an Equity Buyback for KRW 600 million worth of its shares.Ubion Co.Ltd. (KOSDAQ:A084440) announces a share repurchase program. Under the program, the company will repurchase up to KRW 600 million worth of it's shares. The purpose of the program is to enhance shareholder value and provide performance-based compensation for employees and executives. The program will expire on October 14, 2026. As of April 12, 2026, the company had 580,379 shares in treasury within scope available for dividend and had 0 shares under other acquisitions.
Reported Earnings • Feb 24First quarter 2026 earnings released: EPS: ₩2.00 (vs ₩70.00 in 1Q 2025)First quarter 2026 results: EPS: ₩2.00 (down from ₩70.00 in 1Q 2025). Revenue: ₩8.14b (down 27% from 1Q 2025). Net income: ₩32.8m (down 98% from 1Q 2025). Profit margin: 0.4% (down from 13% in 1Q 2025). The decrease in margin was driven by lower revenue.
New Risk • Feb 24New major risk - Revenue and earnings growthEarnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩20.6b market cap, or US$14.3m).
お知らせ • Jan 21Ubion Co.Ltd. (KOSDAQ:A084440) announces an Equity Buyback for KRW 600 million worth of its shares.Ubion Co.Ltd. (KOSDAQ:A084440) announces a share repurchase program. Under the program, the company will repurchase up to KRW 600 million worth of it's shares. The purpose of the program is to enhance shareholder value and provide performance-based compensation for employees and executives. The program will expire on July 22, 2026. As of January 20, 2026, the company had 0 shares in treasury within scope available for dividend and had 0 shares under other acquisitions.
Reported Earnings • Dec 17Full year 2025 earnings released: EPS: ₩68.00 (vs ₩142 loss in FY 2024)Full year 2025 results: EPS: ₩68.00 (up from ₩142 loss in FY 2024). Revenue: ₩33.7b (up 1.2% from FY 2024). Net income: ₩1.34b (up ₩4.14b from FY 2024). Profit margin: 4.0% (up from net loss in FY 2024). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
分析記事 • Aug 22These 4 Measures Indicate That UbionLtd (KOSDAQ:084440) Is Using Debt ExtensivelyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Feb 20First quarter 2025 earnings released: EPS: ₩70.00 (vs ₩11.00 loss in 1Q 2024)First quarter 2025 results: EPS: ₩70.00 (up from ₩11.00 loss in 1Q 2024). Revenue: ₩11.1b (up 36% from 1Q 2024). Net income: ₩1.39b (up ₩1.61b from 1Q 2024). Profit margin: 13% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue.
分析記事 • Dec 18UbionLtd (KOSDAQ:084440) Is Making Moderate Use Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Dec 17Full year 2024 earnings released: ₩142 loss per share (vs ₩28.00 loss in FY 2023)Full year 2024 results: ₩142 loss per share (further deteriorated from ₩28.00 loss in FY 2023). Revenue: ₩33.3b (up 4.6% from FY 2023). Net loss: ₩2.80b (loss widened 414% from FY 2023).
お知らせ • Dec 13Ubion Co.Ltd., Annual General Meeting, Dec 27, 2024Ubion Co.Ltd., Annual General Meeting, Dec 27, 2024, at 11:00 Tokyo Standard Time. Location: seminar room, guro-gu, seoul South Korea
New Risk • Nov 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue has declined by 4.5% over the past year. Minor Risk Market cap is less than US$100m (₩15.1b market cap, or US$10.7m).
Reported Earnings • Sep 02Third quarter 2024 earnings released: ₩23.00 loss per share (vs ₩17.00 loss in 3Q 2023)Third quarter 2024 results: ₩23.00 loss per share (further deteriorated from ₩17.00 loss in 3Q 2023). Revenue: ₩9.22b (up 17% from 3Q 2023). Net loss: ₩468.8m (loss widened ₩420.4m from 3Q 2023).
Reported Earnings • Mar 06First quarter 2024 earnings released: ₩11.00 loss per share (vs ₩11.09 profit in 1Q 2023)First quarter 2024 results: ₩11.00 loss per share (down from ₩11.09 profit in 1Q 2023). Revenue: ₩8.17b (up 17% from 1Q 2023). Net loss: ₩225.7m (down 221% from profit in 1Q 2023).
New Risk • Jun 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Shareholders have been diluted in the past year (32% increase in shares outstanding). Market cap is less than US$100m (₩38.3b market cap, or US$29.6m).
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Is New 90 Day High Low • Feb 24New 90-day high: ₩5,050The company is up 32% from its price of ₩3,825 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Services industry, which is up 4.0% over the same period.
Is New 90 Day High Low • Dec 14New 90-day low: ₩3,150The company is down 6.0% from its price of ₩3,350 on 15 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Services industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Oct 28New 90-day high: ₩3,700The company is up 24% from its price of ₩2,990 on 30 July 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Services industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Sep 25New 90-day high: ₩3,600The company is up 21% from its price of ₩2,980 on 26 June 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Services industry, which is down 3.0% over the same period.